PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2452746-6 1988 By contrast, in conjunction with interleukin 1, HP1 became a major growth and differentiation factor not only for B cells activated with anti-immunoglobulin antibodies but also for dextran sulfate-stimulated and even for unstimulated B cells. Dextran Sulfate 181-196 interleukin 6 Mus musculus 48-51 33640781-0 2021 Gegen Qinlian decoction relieved DSS-induced ulcerative colitis in mice by modulating Th17/Treg cell homeostasis via suppressing IL-6/JAK2/STAT3 signaling. Dextran Sulfate 33-36 interleukin 6 Mus musculus 129-133 33617822-8 2021 Furthermore, DSS-induced increased DAI score and blood IL-6 levels were significantly ameliorated after subsequent repeated administration of (R)-ketamine (10 mg/kg/day for last 7 days), but not 5-aminosalicyclic acid (50 mg/kg/day for last 7 days). Dextran Sulfate 13-16 interleukin 6 Mus musculus 55-59 33640781-14 2021 CONCLUSIONS: Taken together, these results indicated that GQ alleviated DSS-induced UC by suppressing IL-6/JAK2/STAT3 signaling to restore Treg and Th17 cell homeostasis in colonic tissue. Dextran Sulfate 72-75 interleukin 6 Mus musculus 102-106 33352218-4 2021 We observe that alphaT and gammaTmT mitigated DSS-caused fecal bleeding, diarrhea and elevation of IL-6. Dextran Sulfate 46-49 interleukin 6 Mus musculus 99-103 33496702-6 2021 SES also reduced TNF-alpha, IL-1beta and IL-6 production caused by DSS. Dextran Sulfate 67-70 interleukin 6 Mus musculus 41-45 32891820-0 2021 Baitouweng decoction alleviates dextran sulfate sodium-induced ulcerative colitis by regulating intestinal microbiota and the IL-6/STAT3 signaling pathway. Dextran Sulfate 32-54 interleukin 6 Mus musculus 126-130 33509279-7 2021 DSS led to edema, epithelial layer disruption, inflammatory cell infiltration, and cytokine induction (tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta) in the colon tissues. Dextran Sulfate 0-3 interleukin 6 Mus musculus 132-145 33503995-3 2021 Mice were fed diets containing whole LP powder, MetOH extract, and MetOH residue for 16 d. DSS administration for 9 d induced bodyweight loss, reduced colon length, reduced the colonic expression of tight junction proteins including zonula occludens-1 and -2, and claudin-3 and -7, and upregulated colonic mRNA expression of interleukin 6, chemokine (C-X-C motif) ligand 2, and C-C motif chemokine ligand 2. Dextran Sulfate 91-94 interleukin 6 Mus musculus 325-372 33126029-8 2020 Transfer of CD4+ mesLNCs additionally increased adrenal weight and secretion of IL-6 from in vitro anti-CD3 stimulated mesLNCs in recipients administered with DSS. Dextran Sulfate 159-162 interleukin 6 Mus musculus 80-84 31147743-7 2019 The levels of proinflammatory cytokines (TNF-alpha and IL-6) in colonic tissue and serum were reduced significantly and in GAL + DSS-treated group relative to DSS alone treated group. Dextran Sulfate 129-132 interleukin 6 Mus musculus 55-59 33177483-9 2020 RESULTS In the DSS mouse model of IBD, rifaximin reduced the inflammation severity of the colon and reduced the expression of phospho-p65, p65, TNF-alpha, and IL-6. Dextran Sulfate 15-18 interleukin 6 Mus musculus 159-163 32322483-11 2020 Moreover, DSS exposure induced an increase of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, occludin, zonula occludens-1, p21, p53 and Bcl-2, and decreased the expressions of IL-10, claudin-2 and cleaved caspase-3 in the colon tissue. Dextran Sulfate 10-13 interleukin 6 Mus musculus 99-103 31034776-5 2019 DSS-treated AQP4-/- mice had lower serum levels of IL-6 and TNF, higher IL-10 level, and lesser inflammatory cell infiltration. Dextran Sulfate 0-3 interleukin 6 Mus musculus 51-55 32859970-6 2020 Ch25h-/- mice with DSS-induced colitis exhibited aggravated injury, including higher clinical colitis scores, severe injury of the epithelial barrier, lower tight junction protein levels and higher levels of IL-6. Dextran Sulfate 19-22 interleukin 6 Mus musculus 208-212 32859970-7 2020 Supplementation with exogenous 25-HC ameliorated disease symptoms and reduced the extent of damage in DSS-induced colitis, which was characterized by lower colon damage, higher tight junction protein expression, significantly decreased local and systemic production of pro-inflammatory cytokines IL-6. Dextran Sulfate 102-105 interleukin 6 Mus musculus 296-300 32413737-8 2020 Meanwhile, costunolide also suppressed DSS-induced expression of induced nitric oxide synthase (iNOS), interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) in both mRNA and protein levels. Dextran Sulfate 39-42 interleukin 6 Mus musculus 133-137 32395486-8 2020 It was found that DSS can up-regulate the mRNA levels of IL-6 and IL-17 in serum (by qPCR), and the serum and bowel levels of IL-6 and IL-17 (by ELISA); these levels were significantly different from those of the blank group (P<0.05). Dextran Sulfate 18-21 interleukin 6 Mus musculus 57-61 32395486-8 2020 It was found that DSS can up-regulate the mRNA levels of IL-6 and IL-17 in serum (by qPCR), and the serum and bowel levels of IL-6 and IL-17 (by ELISA); these levels were significantly different from those of the blank group (P<0.05). Dextran Sulfate 18-21 interleukin 6 Mus musculus 126-130 32395486-9 2020 Furthermore, 6-gingerol was found to inhibit the increase of mRNA levels and serum and bowel levels of IL-6 and IL-17 induced by DSS, which is similar with mesalazine. Dextran Sulfate 129-132 interleukin 6 Mus musculus 103-107 31313354-6 2019 The effects of SA exhibited in DSS-induced mice were associated with significant decrease in the expressions levels of inflammatory mediators such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), pro-inflammatory cytokines (tumor necrosis factor [TNF-alpha], interleukin [IL-1beta and IL-6]), remarkable amelioration of colonic architectural disruption, and a significant reduction in the activity of colonic myeloperoxidase. Dextran Sulfate 31-34 interleukin 6 Mus musculus 305-309 30184329-5 2018 Furthermore, DSS-induced increases in reactive oxygen species accumulation, TNF-alpha and IL-6 secretion, and malonyldialdehyde activity and a decrease in reduced glutathione in the colon are ameliorated by Hyp. Dextran Sulfate 13-16 interleukin 6 Mus musculus 90-94 30978647-6 2019 Furthermore, it reduced DSS-induced production of reactive oxygen species (ROS), infiltration of macrophages, and expression of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta. Dextran Sulfate 24-27 interleukin 6 Mus musculus 174-178 30092402-8 2018 RT-PCR analysis indicated that the miR-29 RNAs in CD11c+ DCs suppressed the production of interleukin-6 (IL-6), transforming growth factor beta (TGF-beta), and IL-23 subunits in DSS-treated mice. Dextran Sulfate 178-181 interleukin 6 Mus musculus 90-103 30356663-4 2018 Production of the inflammatory cytokines GM-CSF, IL-6, and IFN-gamma was a hallmark of the severe inflammation induced by E. coli strains of Sequence Type 129 (ST129) and ST375 following DSS administration. Dextran Sulfate 187-190 interleukin 6 Mus musculus 49-53 29849131-9 2018 Moreover, SM934 administration dose-dependently decreased the mRNA and protein levels of DSS-induced pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha), and the percentage of macrophages and neutrophils in colon tissues. Dextran Sulfate 89-92 interleukin 6 Mus musculus 139-143 30092402-8 2018 RT-PCR analysis indicated that the miR-29 RNAs in CD11c+ DCs suppressed the production of interleukin-6 (IL-6), transforming growth factor beta (TGF-beta), and IL-23 subunits in DSS-treated mice. Dextran Sulfate 178-181 interleukin 6 Mus musculus 105-109 30384867-15 2018 What"s more, the number of macrophages, the polarization level of M1 macrophages, and the levels of the iconic inflammatory factors IL-6 and IL-12 significantly decreased in IL-16-/- DSS treatment group compared with WT DSS treatment group. Dextran Sulfate 183-186 interleukin 6 Mus musculus 132-136 29684360-6 2018 We further identified IL-6 as a systemic mediator of neutrophil recruitment from the bone marrow of dextran sulfate sodium animals. Dextran Sulfate 100-122 interleukin 6 Mus musculus 22-26 29622848-7 2018 IL-6, TNF-alpha, and Ccl2 gene expression peaked on day 5 in DSS-treated mouse colon, whereas SAHA treatment significantly decreased pro-inflammatory gene expression. Dextran Sulfate 61-64 interleukin 6 Mus musculus 0-4 29845215-0 2018 Pien Tze Huang ameliorates DSS-induced colonic inflammation in a mouse colitis model through inhibition of the IL-6/STAT3 pathway. Dextran Sulfate 27-30 interleukin 6 Mus musculus 111-115 29845215-9 2018 Furthermore, PZH treatment significantly inhibited DSS-induced expression of IL-6 in colon tissues. Dextran Sulfate 51-54 interleukin 6 Mus musculus 77-81 29890681-7 2018 mRNA expression of pro-inflammatory cytokines indicated that broccoli anti-inflammatory action may be through inhibition of the IL-6 trans-signaling pathway, as evidenced by reversal of the DSS-increased expression of IL-6, CCR2 and vascular cell adhesion molecule 1 (VCAM-1). Dextran Sulfate 190-193 interleukin 6 Mus musculus 128-132 29890681-7 2018 mRNA expression of pro-inflammatory cytokines indicated that broccoli anti-inflammatory action may be through inhibition of the IL-6 trans-signaling pathway, as evidenced by reversal of the DSS-increased expression of IL-6, CCR2 and vascular cell adhesion molecule 1 (VCAM-1). Dextran Sulfate 190-193 interleukin 6 Mus musculus 218-222 29724065-11 2018 We conclude that TRYP improves the health condition of mice with DSS induced colitis by regulating the TNF-alpha/NF-kappaBp65 and IL-6/STAT3 signaling pathways via inhibiting the degradation of IkappaBalpha and the phosphorylation of STAT3. Dextran Sulfate 65-68 interleukin 6 Mus musculus 130-134 29922289-10 2018 In DSS colitis, increased levels of IL-6, CSF3, and IL-17 were further increased in Smox-/- mice. Dextran Sulfate 3-6 interleukin 6 Mus musculus 36-40 29611140-9 2018 The mRNA expression levels of tumor necrosis factor (TNF)-alpha and interferon (INF)-gamma were significantly upregulated; however, those of interleukin (IL)-6 and IL-10 were significantly downregulated in the DSS-CT group than in the control group. Dextran Sulfate 210-213 interleukin 6 Mus musculus 141-159 30423565-10 2018 Consistent with the milder inflammatory pathological changes, DSS-treated KO mice had lower levels of IL-1beta, IL-6 and TNF-alpha mRNA in the liver and the colon. Dextran Sulfate 62-65 interleukin 6 Mus musculus 112-116 28962154-1 2017 The present study aimed to assess interleukin (IL)-6 expression in a murine model of ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) and its potential association with the anti-colitis effects of triptolide (TL). Dextran Sulfate 120-142 interleukin 6 Mus musculus 34-52 28759012-7 2017 Furthermore, in vivo administration of IL-6 to DSS-treated ApcMin/+ mice effectively weakened the inhibitory effects of berberine on tumorigenesis and EGFR-ERK signaling in colon tissues. Dextran Sulfate 47-50 interleukin 6 Mus musculus 39-43 28956670-7 2017 More specifically, glyceollins reduced plasma levels of inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin-6, which were otherwise markedly increased by DSS treatment. Dextran Sulfate 178-181 interleukin 6 Mus musculus 120-133 28962154-1 2017 The present study aimed to assess interleukin (IL)-6 expression in a murine model of ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) and its potential association with the anti-colitis effects of triptolide (TL). Dextran Sulfate 144-147 interleukin 6 Mus musculus 34-52 28962154-4 2017 The expression of IL-6 was weak in mucosa specimens from normal control animals and upregulated in DSS-induced mice. Dextran Sulfate 99-102 interleukin 6 Mus musculus 18-22 28293084-9 2017 Inflammatory factors were assessed, and the results showed that the DSS + HRW group exhibited significantly reduced levels of TNF-alpha, IL-6 and IL-1beta compared with the DSS group (P < 0.05). Dextran Sulfate 68-71 interleukin 6 Mus musculus 137-141 28740344-7 2017 Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels. Dextran Sulfate 74-77 interleukin 6 Mus musculus 122-126 27951472-8 2017 DSS increased colonic interleukin (IL)-1beta, IL-6, and monocyte chemotactic protein-1 expression. Dextran Sulfate 0-3 interleukin 6 Mus musculus 46-50 27811936-8 2016 DSS-treated TG2-/- mice showed lower interleukin (IL)-6, but higher IL-17A and RORgammat (retinoic acid receptor-related orphan receptor-gammat) expression levels in the colon tissues than that in the wild-type mice. Dextran Sulfate 0-3 interleukin 6 Mus musculus 37-55 28584524-12 2017 Moreover, DSS treatment markedly increased serum IL-6 and FGF21 levels. Dextran Sulfate 10-13 interleukin 6 Mus musculus 49-53 28584821-3 2017 RESULTS: DSS-resistant BALB/c mice were characterized by low levels of IFN-gamma and TNF-alpha but high levels of IL-4, IL-6, IL-10, IL-17A, IL-17F, and colon lamina propria and mesenteric lymph node (MLN) CD4+CD25+FoxP3+ T cells when compared to C57BL/6 mice. Dextran Sulfate 9-12 interleukin 6 Mus musculus 120-124 27311853-0 2016 N"-[(3-[benzyloxy]benzylidene]-3,4,5-trihydroxybenzohydrazide (1) protects mice against colitis induced by dextran sulfate sodium through inhibiting NFkappaB/IL-6/STAT3 pathway. Dextran Sulfate 107-129 interleukin 6 Mus musculus 158-162 27563884-9 2016 Taken together, LFs treatment alleviated AOM/DSS induced CAC via P53 and NFkappaB/IL-6/Jak2/Stat3 pathways, highlighting the potential of LFs in preventing CAC. Dextran Sulfate 45-48 interleukin 6 Mus musculus 82-86 27112251-7 2016 DSS increased disease severity, serum CRP and cytokines IL-1beta and IL-6, but decreased bacterial species richness, and shifted bacterial community composition. Dextran Sulfate 0-3 interleukin 6 Mus musculus 69-73 27105502-6 2016 Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF, IL-1beta, IL-6, IL-18, IL-17A and IFN-gamma, were markedly suppressed by MALT1 inhibitors. Dextran Sulfate 37-40 interleukin 6 Mus musculus 110-114 27207670-9 2016 Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels. Dextran Sulfate 17-20 interleukin 6 Mus musculus 179-192 27207670-9 2016 Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels. Dextran Sulfate 17-20 interleukin 6 Mus musculus 194-198 27207670-9 2016 Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels. Dextran Sulfate 41-44 interleukin 6 Mus musculus 179-192 27207670-9 2016 Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels. Dextran Sulfate 41-44 interleukin 6 Mus musculus 194-198 27155817-0 2016 Neutralization of IL-6 and TNF-alpha ameliorates intestinal permeability in DSS-induced colitis. Dextran Sulfate 76-79 interleukin 6 Mus musculus 18-22 26620764-5 2016 FC-99 also suppressed the DSS-induced secretion of interleukin (IL)-1beta, IL-6, and the tumor necrosis factor (TNF)-alpha in the colon and hindered the infiltration of macrophages into colon lamina propria. Dextran Sulfate 26-29 interleukin 6 Mus musculus 75-79 27074537-7 2016 SAE200 also significantly attenuated DSS-induced increase in IL-6 and IL-1beta, and reductions in IL-10 in colon tissue. Dextran Sulfate 37-40 interleukin 6 Mus musculus 61-65 26739550-11 2016 Production of inflammatory cytokines, i.e., interleukin-6 and tumor necrosis factor (TNF)-alpha, was significantly increased in DSS-induced colitis mice. Dextran Sulfate 128-131 interleukin 6 Mus musculus 44-57 26770316-0 2015 Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17. Dextran Sulfate 44-66 interleukin 6 Mus musculus 129-133 26770316-0 2015 Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17. Dextran Sulfate 68-71 interleukin 6 Mus musculus 129-133 26251468-3 2015 In the present study, we found that cardamonin markedly ameliorated dextran sulfate sodium-induced mouse body weight loss, diarrhea, colon shortening, spleen swelling, and histological damage, which correlated with a decline in the activity of myeloperoxidase and the production of nitric oxide, tumor necrosis factor-alpha and interleukin-6 in the colon. Dextran Sulfate 68-90 interleukin 6 Mus musculus 328-341 25926522-4 2015 DSS treatment (2.5% in drinking water for 6 days) caused more severe colon inflammation, as evidenced by the presence of higher levels of myeloperoxidase and proinflammatory cytokines [tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1beta], and greater weight loss, colonic tissue damage, and colon shortening, in IE-Cpr-null mice than in WT mice. Dextran Sulfate 0-3 interleukin 6 Mus musculus 214-232 25896053-9 2015 The results revealed that compared with control, the DSS mouse showed weight loss (P < 0.05), a shortened colon (P < 0.05), and swelled spleen (P < 0.05), accompanied by higher histological score (P < 0.05), as well as infiltration of macrophages, elevated TNF-alpha and IL-6 levels in plasma (P < 0.01). Dextran Sulfate 53-56 interleukin 6 Mus musculus 283-287 26066467-6 2015 Furthermore, the combination of DSS and WAS increased interleukin-6 and growth regulated oncogene-alpha levels in the brain. Dextran Sulfate 32-35 interleukin 6 Mus musculus 54-67 25896053-12 2015 In vitro, TNF-alpha and IL-6 levels were increased in the supernatant of macrophages from DSS mice colonic tissue (P < 0.05), and after incubation of TNF-alpha or IL-6 with colonic mucosal microvascular endothelial cells, the APC activity was decreased (P < 0.05 or P < 0.01), and expression of EPCR was down regulated (P < 0.05). Dextran Sulfate 90-93 interleukin 6 Mus musculus 24-28 25837923-9 2015 Additionally, stimulation of alpha7 nAChRs decreased the colon level of interleukin-6 and interferon-gamma upon DSS administration. Dextran Sulfate 112-115 interleukin 6 Mus musculus 72-85 25523461-4 2015 Protein and mRNA levels of DSS-induced pro-inflammatory cytokines in colon, including TNF-alpha, IL-1beta, IL-6 and IFN-gamma, were markedly suppressed by asiatic acid. Dextran Sulfate 27-30 interleukin 6 Mus musculus 107-111 23596159-5 2013 DSS administration caused severe colon damage and inflammation, as indicated by body weight loss, increased clinical sores, colon shortening, and gene expressions of inflammatory cytokines [interferon-gamma, interleukin (IL)-6, macrophage inflammatory protein-2, and IL-17A). Dextran Sulfate 0-3 interleukin 6 Mus musculus 208-226 25258409-8 2014 Furthermore, nicotine inhibited the IL-6 production of CD4 T cells in the DSS-induced inflamed colonic mucosa. Dextran Sulfate 74-77 interleukin 6 Mus musculus 36-40 25194678-5 2014 DSS-induced degradation of inhibitory kappaBalpha (IkappaBalpha) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 as well as the mRNA expression of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), TNF-alpha, interleukin-1beta (IL-1beta) and IL-6) in the colon were also downregulated by mangiferin treatment. Dextran Sulfate 0-3 interleukin 6 Mus musculus 311-315 24852097-12 2014 Up-regulation of inflammatory cytokines including monocyte chemotactic protein-1, tumor necrosis factor-alpha, and interleukin-6 in this DSS-induced colitis was significantly suppressed in SMA/CORM2-treated mice. Dextran Sulfate 137-140 interleukin 6 Mus musculus 115-128 24587679-9 2014 IL-6, IL-10 and IFN-gamma reached their maxima 4 d after DSS withdrawal and decreased during the late recovery phase. Dextran Sulfate 57-60 interleukin 6 Mus musculus 0-4 23732773-7 2013 RESULTS: Colon tissues and mesenteric lymph nodes of Card9-null mice had reduced levels of interleukin (IL)-6, interferon-gamma, and T-helper (Th)17 cytokines after administration of DSS, compared with wild-type mice. Dextran Sulfate 183-186 interleukin 6 Mus musculus 91-109 26218715-4 2015 pGLP-2 microspheres showed 20.36% in initial burst and constant release for at least 9 d. In the DSS-treated mice, a single injection of GLP-2 microspheres significantly increased the body weight, colonic length, small intestinal weight and mRNA expression of Occludin, decreased the colonic damage score, mRNA expression of IL-6, IL-10, TNF-alpha and IFN-gamma. Dextran Sulfate 97-100 interleukin 6 Mus musculus 325-329 23954958-9 2013 The expression of IL-6 in colonic tissue was significantly lower in the B-98 groups than the DSS colitis group (p<0.05). Dextran Sulfate 93-96 interleukin 6 Mus musculus 18-22 23596159-10 2013 DSS administration moderately induced colon shortening at d 3 and 6 and increased the disease activity index (DAI) and inflammatory cytokine (IL-6 and IL-17A) expression without any significant increases in colonic permeability. Dextran Sulfate 0-3 interleukin 6 Mus musculus 142-146 20181886-5 2010 Comprehensive serum multiplex cytokine profiling demonstrated a heightened Th1-Th17 profile (increased TNF-alpha, IL-6, and IL-17) in DSS-induced Clcn5 KO mice compared with that in WT DSS colitis mice. Dextran Sulfate 134-137 interleukin 6 Mus musculus 114-118 22962574-7 2012 RESULTS: IL-6 concentrations increased significantly in the colon tissues of DSS-treated mice. Dextran Sulfate 77-80 interleukin 6 Mus musculus 9-13 23557800-9 2013 In DSS-treated mice, colon tissues from mIL-21iso-Tg mice had significantly higher gene activation levels for cytokines such as IL-17A, TNF-alpha, IL-6, IL-10, and IL-4, and for transcription factors such as T-bet, GATA-3, RORgammat, and Foxp3, than were found in wild-type mice. Dextran Sulfate 3-6 interleukin 6 Mus musculus 147-151 23230342-6 2012 We also observed a significant increase in production of pro-inflammatory cytokines, IL-6 and IFN-gamma, in spleen lymphocytes treated with DSS; however, such an increase was not observed in infected mice treated with DSS. Dextran Sulfate 140-143 interleukin 6 Mus musculus 85-89 21987656-4 2011 After AOM+DSS treatment, IL-21 KO mice showed reduced mucosal damage, reduced infiltration of T cells, and diminished production of IL-6 and IL-17A. Dextran Sulfate 10-13 interleukin 6 Mus musculus 132-136 20550948-7 2010 Northern blot analyses and immunohistochemistry of colonic tissue revealed that C10 markedly diminished DSS-induced expression of pertinent inflammatory mediators: TNF-alpha, IL-1beta, IL-6, IL-12, IP-10, TLR-4 and VCAM-1. Dextran Sulfate 104-107 interleukin 6 Mus musculus 185-189 19834971-9 2010 Moreover, our results clearly demonstrate that IL-19 is required for B-cell infiltration during chronic DSS-induced colitis, which may be mediated by IL-13 and IL-6. Dextran Sulfate 104-107 interleukin 6 Mus musculus 160-164 20111595-5 2010 In comparison to control animals, we observed significant changes in the colon mucosa of DSS-treated TC-PTP(+/-) mice, in the ratio of colon to body weight, as well as an up-regulation of mRNA transcripts for IL-6, IL-23, 1L-12beta, IFN-gamma, TNF-alpha. Dextran Sulfate 89-92 interleukin 6 Mus musculus 209-213 20111595-6 2010 Moreover, up-regulation of serum IL-6 levels in DSS-treated TC-PTP(+/-) mice confirms that mice with a single copy of the TC-PTP gene display increased susceptibility to systemic inflammation due to bowel epithelial erosion resulting from DSS challenge. Dextran Sulfate 48-51 interleukin 6 Mus musculus 33-37 20111595-6 2010 Moreover, up-regulation of serum IL-6 levels in DSS-treated TC-PTP(+/-) mice confirms that mice with a single copy of the TC-PTP gene display increased susceptibility to systemic inflammation due to bowel epithelial erosion resulting from DSS challenge. Dextran Sulfate 239-242 interleukin 6 Mus musculus 33-37 19190174-6 2009 DSS induced a T(H)2 colitis [increased interleukin (IL)-4 and IL-6] with no changes in T(H)1 cytokines. Dextran Sulfate 0-3 interleukin 6 Mus musculus 62-66 15652231-8 2005 Further, DSS-induced increases in colonic mucosal IL-1 beta levels were blunted significantly in rutin-, but not quercetin-, fed mice (P<0.01), while dietary rutin attenuated the expressions of IL-1 beta and IL-6 mRNA in colonic mucosa (each, P<0.01). Dextran Sulfate 9-12 interleukin 6 Mus musculus 211-215 18205183-7 2008 In proximal colon, production of IL-1beta and IL-6 in PACAP-/- mice were significantly upregulated on day 8 after DSS administration, compared to wild-type control mice. Dextran Sulfate 114-117 interleukin 6 Mus musculus 46-50 16794011-7 2006 Subsequent treatment with 1% DSS for 7 d resulted in a more severe intestinal inflammation in SD/OC mice, as reflected by an increase in body weight loss, histological damage scores, and secretion of IL-6, TNFalpha, and interferon-gamma from mesenteric lymph node cells and by decreased colon length. Dextran Sulfate 29-32 interleukin 6 Mus musculus 200-204 16157881-5 2005 In this context, flagellin exposure to injured colonic mucosa due to DSS administration in mice resulted in a TLR5-associated response evaluated by in vivo activation of mitogen-activated protein kinase/extracellular signal-related kinase 1/2 (MEK1/2) and elevated IL-6, TNF-alpha, and keratinocyte-derived chemokine production, whereas intact colonic mucosa did not respond to flagellin. Dextran Sulfate 69-72 interleukin 6 Mus musculus 265-269 19234608-11 2009 IL-6, TNFalpha, and MCP-1 mRNA expression were increased in the colon of TLE-fed, DSS-exposed NF-kappaB(EGFP) mice compared to the control diet. Dextran Sulfate 82-85 interleukin 6 Mus musculus 0-4 19030026-9 2008 The level of IL-6 was increased by 1.5- and 2-fold in the colon of GM-CSF(-/-) and Wt mice, respectively, following DSS challenge. Dextran Sulfate 116-119 interleukin 6 Mus musculus 13-17 16202978-0 2005 Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Dextran Sulfate 55-77 interleukin 6 Mus musculus 26-39 16202978-10 2005 attenuated DSS-induced body weight reduction and shortening of the colorectum (P < 0.05, each), and abrogated the expressions of IL-1beta and IL-6 mRNA in colonic mucosa (P < 0.01, each). Dextran Sulfate 11-14 interleukin 6 Mus musculus 145-149 11181699-6 2001 Development of colitis as well as STAT3 activation was significantly reduced in IL-6-deficient mice treated with DSS, suggesting that STAT3 plays an important role in the perpetuation of colitis. Dextran Sulfate 113-116 interleukin 6 Mus musculus 80-84 15254764-7 2004 At each assessment, colonic injury was significantly attenuated in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice. Dextran Sulfate 67-70 interleukin 6 Mus musculus 79-83 15254764-7 2004 At each assessment, colonic injury was significantly attenuated in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice. Dextran Sulfate 106-109 interleukin 6 Mus musculus 118-122 15254764-8 2004 Histological study also showed a reduced infiltration of inflammatory cells, especially neutrophils, and mucosal cell disruption in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice. Dextran Sulfate 132-135 interleukin 6 Mus musculus 144-148 15254764-8 2004 Histological study also showed a reduced infiltration of inflammatory cells, especially neutrophils, and mucosal cell disruption in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice. Dextran Sulfate 171-174 interleukin 6 Mus musculus 183-187 15254764-9 2004 In the colons of DSS-treated IL-6-/- mice, the expression of both TNF-alpha mRNA and iNOS mRNA was reduced on day 5. Dextran Sulfate 17-20 interleukin 6 Mus musculus 29-33 15254764-10 2004 In contrast, IL-10 mRNA expression was enhanced compared with DSS-treated IL-6+/+ mice. Dextran Sulfate 62-65 interleukin 6 Mus musculus 74-78 15254764-11 2004 In conclusion, DSS-induced inflammation appears to be significantly inhibited in IL-6-/- mice compared to wild-type mice. Dextran Sulfate 15-18 interleukin 6 Mus musculus 81-85 34174740-5 2021 In a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis (UC), compound 4 showed anti-inflammatory property and reduced the levels of pro-inflammatory cytokines (TNF-alpha and IL-6). Dextran Sulfate 5-27 interleukin 6 Mus musculus 195-199 34964214-8 2022 Furthermore, protein expression of phosphorylated nuclear factor kappa light chain enhancer of activated B cells (pNFkappaB65), proliferating cell nuclear antigen, interleukin-6, apoptosis-associated speck-like protein containing a caspase-recruitment domain, and cysteine-containing aspartate-specific proteases-1 (caspase-1) significantly increased in the DSS + DB group of male animals as compared to female. Dextran Sulfate 358-361 interleukin 6 Mus musculus 164-218 34903499-8 2021 RESULTS: DSS-induced colitis increased steatosis, inflammatory (IL-6, TNFalpha, NLRP3, MCP-1) as well as fibrotic (TGF-beta, alpha-SMA) mediator expression in HFD-FG mice. Dextran Sulfate 9-12 interleukin 6 Mus musculus 64-68 34174740-5 2021 In a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis (UC), compound 4 showed anti-inflammatory property and reduced the levels of pro-inflammatory cytokines (TNF-alpha and IL-6). Dextran Sulfate 29-32 interleukin 6 Mus musculus 195-199 34217990-7 2021 Thus, it was concluded that IL-6 represses hepatic CESs via the NF-kappaB pathway in DSS-induced colitis. Dextran Sulfate 85-88 interleukin 6 Mus musculus 28-32 34765000-14 2021 Subsequently, animal-based experiments revealed the intraperitoneal injection of friedelin ameliorated DSS-induced body weight loss, DAI decrease, colon length shortening and colonic pathological damage with lower myeloperoxidase and proinflammatory cytokines (IL-1beta and IL-6) and higher IL-10 levels, and more autophagosomes in transmission electron microscope results. Dextran Sulfate 103-106 interleukin 6 Mus musculus 274-278 34421890-8 2021 JUG reversed the DSS-induced up-regulation of proinflammatory cytokines, including interleukin (IL)-6, 12, 21, and 23, and tumor necrosis factor-alpha, and anti-inflammatory cytokines, such as IL-10 and transforming growth factor-beta, in the serum of the colitis mice. Dextran Sulfate 17-20 interleukin 6 Mus musculus 83-101 34115225-12 2021 Importantly, a significant decrease in pro-inflammatory mediators (NO, IL-6 and TNF-alpha) levels in dose-dependent manner was reported in plasma, and culture supernatants of colonic explants and peritoneal macrophages from DSS + PLAE-treated mice compared to the DSS group. Dextran Sulfate 224-227 interleukin 6 Mus musculus 71-75 34115225-12 2021 Importantly, a significant decrease in pro-inflammatory mediators (NO, IL-6 and TNF-alpha) levels in dose-dependent manner was reported in plasma, and culture supernatants of colonic explants and peritoneal macrophages from DSS + PLAE-treated mice compared to the DSS group. Dextran Sulfate 264-267 interleukin 6 Mus musculus 71-75 34280033-8 2021 Compared to those in the DSS-induced mice, histological damage and IL-6 cytokine levels were significantly reduced in SCGB1-fed mice. Dextran Sulfate 25-28 interleukin 6 Mus musculus 67-71 34152136-6 2021 The results demonstrated that PTS significantly attenuated HFD and DSS-induced plasma interleukin-6 accumulation. Dextran Sulfate 67-70 interleukin 6 Mus musculus 86-99 35001008-0 2022 Latilactobacillus curvatus BYB3 Isolated from Kimchi Alleviates Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice by Inhibiting IL-6 and TNF-R1 Production. Dextran Sulfate 64-86 interleukin 6 Mus musculus 131-135 35001008-0 2022 Latilactobacillus curvatus BYB3 Isolated from Kimchi Alleviates Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice by Inhibiting IL-6 and TNF-R1 Production. Dextran Sulfate 88-91 interleukin 6 Mus musculus 131-135 35001008-6 2022 In addition, significantly lower levels of IL-6 and tumor necrosis factor receptor 1 upregulation were seen in the DSS+BYB3 group (compared to that in the DSS group). Dextran Sulfate 115-118 interleukin 6 Mus musculus 43-47 35001008-6 2022 In addition, significantly lower levels of IL-6 and tumor necrosis factor receptor 1 upregulation were seen in the DSS+BYB3 group (compared to that in the DSS group). Dextran Sulfate 155-158 interleukin 6 Mus musculus 43-47 35372817-5 2022 In a dextran sulfate sodium-induced acute colitis murine model, LUT@TPGS-PBTE NPs alleviated body weight loss, colon length shortening, and damage to the colonic tissues due to the suppression of ROS and proinflammatory cytokines (e.g., IL-17A, IL-6, interferon-gamma, tumor necrosis factor-alpha), as well as upregulation of glutathione and anti-inflammatory factors (e.g., IL-10, IL-4). Dextran Sulfate 5-27 interleukin 6 Mus musculus 245-249 35055106-4 2022 DSS-exposed Parp7-/- mice had less body weight loss, lower disease index scores, and reduced expression of several inflammation genes, including interleukin IL-6, C-x-c motif chemokine ligand 1 (Cxcl1), and lipocalin-2, when compared with wild-type mice. Dextran Sulfate 0-3 interleukin 6 Mus musculus 157-161 34163116-15 2021 These results indicate that the conditioned mADSCs secretome suppressed the synthesis of inflammatory cytokines in damaged colon tissue and the elevation of serum IL-6 concentration in DSS-induced mice. Dextran Sulfate 185-188 interleukin 6 Mus musculus 163-167 34998820-7 2022 BaP also suppressed colonic expression of inflammation-associated genes and plasma interleukin-6 secretion induced by DSS treatment. Dextran Sulfate 118-121 interleukin 6 Mus musculus 83-96